Mobile phone recycling is {starting to increase in popularity with numerous individuals from around the world, but what mobile phone is selling for the most? And which cell phone is the best selling?

Well predictably the iPhone 3G is the most valuable at the moment clocking in at a staggering £350 at MobilePhoneXchange, so if you are in possession of a new Apple iPhone that you no longer use, or just can’t get used to then you could make yourself a quite a bit of money.

The most popular phone that can be used for mobile phone recycling at the present time is the Nokia N95 and if you have one that you wish to get rid of you can get up to £118 if you trade it in now at Love2Recycle. So it’s time to dust down your old mobile phones and put some money in your pocket!

It has been a long-time coming. It has been hyped and scoffed, bet against and hoped for, but now none of that matters. It’s here. Dendreon has brought Provenge to market. Here, in the word’s of the FDA…

FDA NEWS RELEASE

For Immediate Release: April 29, 2010

FDA Approves a Cellular Immunotherapy for Men with Advanced Prostate Cancer

The U.S. Food and Drug Administration today approved Provenge (sipuleucel-T), a new therapy for certain men with advanced prostate cancer that uses their own immune system to fight the disease.

Provenge is indicated for the treatment of asymptomatic or minimally symptomatic prostate cancer that has spread to other parts of the body and is resistant to standard hormone treatment.

Prostate cancer is the second most common type of cancer among men in the United States, behind skin cancer, and usually occurs in older men. In 2009, an estimated 192,000 new cases of prostate cancer were diagnosed and about 27,000 men died from the disease, according to the National Cancer Institute.

“The availability of Provenge provides a new treatment option for men with advanced prostate cancer, who currently have limited effective therapies available,” said Karen Midthun, M.D., acting director of the FDA’s Center for Biologics Evaluation and Research.

Provenge is an autologous cellular immunotherapy, designed to stimulate a patient’s own immune system to respond against the cancer. Each dose of Provenge is manufactured by obtaining a patient’s immune cells from the blood, using a machine in a process known as leukapheresis. To enhance their response against the cancer, the immune cells are then exposed to a protein that is found in most prostate cancers, linked to an immune stimulating substance. After this process, the patient’s own cells are returned to the patient to treat the prostate cancer. Provenge is administered intravenously in a three-dose schedule given at about two-week intervals.

The effectiveness of Provenge was studied in 512 patients with metastatic hormone treatment refractory prostate cancer in a randomized, double-blind, placebo-controlled, multicenter trial, which showed an increase in overall survival of 4.1 months. The median survival for patients receiving Provenge treatments was 25.8 months, as compared to 21.7 months for those who did not receive the treatment.

Almost all of the patients who received Provenge had some type of adverse reaction. Common adverse reactions reported included chills, fatigue, fever, back pain, nausea, joint ache and headache. The majority of adverse reactions were mild or moderate in severity. Serious adverse reactions, reported in approximately one quarter of the patients receiving Provenge, included some acute infusion reactions and stroke. Cerebrovascular events, including hemorrhagic and ischemic strokes, were observed in 3.5 percent of patients in the Provenge group compared with 2.6 percent of patients in the control group.

Provenge is manufactured by Seattle-based Dendreon Corp.

www.celltherapyblog.com hosted by www.celltherapygroup.com

Owners of elderly dogs can get help and information on a new Web site.Pet Ventures LLC has launched www.seniordogs.com for owners of older dogs. In the United States, about 40 percent of households with dogs have at least one that is considered a senior (7 or older), statistics on the Web site indicated.”Thanks to preventative care, better nutrition and advances in …

THURSDAY, April 29 (HealthDay News) — The U.S. Food and Drug Administration on Thursday granted approval to Provenge, a therapeutic vaccine aimed at preventing the spread of prostate cancer in men with an advanced form of the disease.

Image Caption: This is a canine retina, injected with an AAV2/5 carrying the GRK1 promoter and the GFP gene. A red antibody that specifically identifies cones was used to label this class of photoreceptor cells, and confirm that GFP targeted rods. Blue labeling identifies the retina cells. Credit: University of Pennsylvania

Veterinary vision scientists at the University of Pennsylvania have safely and successfully used a viral vector in targeting a class of photoreceptors of the retina called rods, a critical first step in developing gene therapies for inherited blindness caused by rod degeneration.

In trying to plant his tomatoes upside down, Terry Dickson ended up with his shirt and shoes full of dirt. We offer instead this insightful correspondence from Bubba Gene Hightower, mayor of Pond Scoggin, Ga. Dear Mr. Dickerson, I hope this finds you and yours fine and otherwise dandy. As for me and Guynell and Bubba Guy, that’s our onliest boy, we’re all trying to figure out this here weather …

Ceregene, Inc., a biopharmaceutical company, announced that enrollment is proceeding in a new Phase 1/2 clinical study evaluating CERE-120, a gene therapy product which delivers the neurotrophic factor neurturin, to dying neurons in Parkinson’s disease patients. This new clinical study follows a completed Phase 2 trial and builds on experience gained in that trial, by enhancing the dosing regimen and optimizing the duration of patient follow up. The new study was initiated in the fourth quarter of 2009 and is proceeding as planned… (Source: Health News from Medical News Today)

Findings describe a biodegradable gene therapy nanotechnology that can silence genes more stably. (Source: Cancer Research)

Findings describe a novel cell-based technology for delivery of a proapoptotic cancer gene therapy. (Source: Cancer Research)

(University of Pennsylvania) Veterinary vision scientists at the University of Pennsylvania have safely and successfully used a viral vector in targeting a class of photoreceptors of the retina called rods, a critical first step in developing gene therapies for inherited blindness caused by rod degeneration. (Source: EurekAlert! – Biology)

Authors: J M Dadgari, R E Moore, K A Louie, T D Lee
& M McMillan (Source: Gene Therapy)

Authors: G D Trobridge
& H-P Kiem (Source: Gene Therapy)

rAAV2/5 gene-targeting to rods:dose-dependent efficiency and complications associated with different promoters

Gene Therapy advance online publication, April 29, 2010. doi:10.1038/gt.2010.56

Authors: W A Beltran, S L Boye, S E Boye, V A Chiodo, A S Lewin, W W Hauswirth
& G D Aguirre (Source: Gene Therapy)